Plain-English translation of NCT06475989 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing two different targeted medications — with , or — for people with a specific type of thyroid cancer that has progressed despite previous treatment. Researchers want to find out which medication works better at slowing cancer growth and improving survival, and which one patients tolerate better with fewer side effects.
People with advanced thyroid cancer often stop responding to the first medications they try. This trial exists to help doctors understand which targeted therapy works best when cancer continues to grow despite initial treatment, so future patients can get the most effective medication from the start.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of two medications daily for 28-day cycles, continuing as long as the treatment works and you tolerate it well. You'll visit the clinic regularly for blood tests and imaging scans (CT or MRI) to monitor how your cancer is responding. If your cancer progresses, you have the option to switch to the other medication being tested. Throughout the study, you'll also complete brief surveys about how the treatment affects your daily life and quality of life.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States